Federal Circuit Invalidates Enanta's Paxlovid Patent, Affirming Lower Court Ruling
ENTA has more than doubled off its 52-week low of $6.435 on elevated volume (2.3× avg).
Summary
Enanta Pharmaceuticals lost its appeal at the Federal Circuit, which affirmed a lower court's decision to invalidate its patent related to Pfizer's COVID-19 antiviral, Paxlovid.
Key Events · Legal and Risk Events · ENTA
-
Patent Invalidated
The Federal Circuit affirmed a lower court's decision, ruling that the claims of U.S. Patent No. 11,358,953, related to Pfizer's Paxlovid, are invalid.
-
Loss of Potential Damages
This ruling eliminates Enanta's ability to pursue damages from Pfizer for alleged infringement of the now-invalidated patent.
Analysis · ENTA · Life Sciences
This ruling eliminates Enanta's ability to seek damages from Pfizer for alleged infringement of the '953 patent related to Paxlovid. The invalidation of a key patent at the Federal Circuit represents a significant setback for the company's intellectual property portfolio and removes a potential source of substantial future revenue. This follows the previous disclosure on March 26, 2026, regarding the scheduling of oral arguments for this appeal.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $14.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $408.8M. The 52-week trading range was $6.44 to $17.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.